[Federal Register: February 21, 2003 (Volume 68, Number 35)]
[Notices]               
[Page 8513]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr21fe03-35]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

 
Clinical Laboratory Improvement Advisory Committee (CLIAC): 
Meeting

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting.
    Name: Clinical Laboratory Improvement Advisory Committee (CLIAC).
    Times and Dates: 8:30 a.m.-5 p.m., March 12, 2003.
    8:30 a.m.-3:30 p.m., March 13, 2003.
    Place: Sheraton Colony Square Hotel, 188 14th Street NE, Atlanta, 
Georgia 30361.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services, the Assistant Secretary for Health, and the Director, CDC, 
regarding the need for, and the nature of, revisions to the standards 
under which clinical laboratories are regulated; the impact on medical 
and laboratory practice of proposed revisions to the standards; and the 
modification of the standards to accommodate technological advances.
    Matters to Be Discussed: The agenda will include updates from CDC, 
the Centers for Medicare & Medicaid Services, and the Food and Drug 
Administration; a report on the recently published CLIA Quality Systems 
final rule; a report on rapid HIV testing; a demonstration of 
CytoViewTM; and various perspectives and discussion on 
direct access testing. Agenda items are subject to change as priorities 
dictate.
    Providing Oral or Written Comments: It is the policy of the CLIAC 
to accept written public comments and provide a brief period for oral 
public comments whenever possible. Oral Comments: In general, each 
individual or group requesting to make an oral presentation will be 
limited to a total time of five minutes (unless otherwise indicated). 
Speakers must also submit their comments in writing for inclusion in 
the meeting's Summary Report. Written Comments: For individuals or 
groups unable to attend the meeting, the CLIAC accepts written comments 
until the date of the meeting (unless otherwise stated). However, the 
comments should be received at least one week prior to the meeting date 
so that the comments may be made available to the committee for their 
consideration and public distribution. Written comments, one hard copy 
with original signature, should be provided to the contact person 
below. Written comments will be included in the meeting's Summary 
Report.
    Contact Person for Additional Information: Rhonda Whalen, Chief, 
Laboratory Practice Standards Branch, Division of Laboratory Systems, 
Public Health Practice Program Office, CDC, 4770 Buford Highway, NE, 
Mailstop F-11, Atlanta, Georgia 30341-3717; telephone (770)488-8042; 
fax (770)488-8279; or via e-mail at RWhalen@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

    Dated: February 13, 2003.
Joseph E. Salter,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 03-4059 Filed 2-20-03; 8:45 am]

BILLING CODE 4163-18-P